Intrajugular VEIN DELIVERY OF AAV9-RNAi prevents neuropathological changes and weight loss in huntington's disease mice

Molecular Therapy

Volumn 22, Issue 4, 2014, Pages 797-810

  Dufour, Brett D ^a,b   Smith, Catherine A ^b   Clark, Randall L ^b   Walker, Timothy R ^b   Mcbride, Jodi L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; LACTATE DEHYDROGENASE; MESSENGER RNA; PARVOVIRUS VECTOR; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC CODE; HTT GENE; HUNTINGTON CHOREA; JUGULAR VEIN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; RNA INTERFERENCE; SEROTYPE; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; WEIGHT REDUCTION; WILD TYPE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; HUNTINGTON DISEASE; MUTATION; PATHOLOGY;

MUS; MUS MUSCULUS;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HUNTINGTON DISEASE; JUGULAR VEINS; MICE; MUTATION; NERVE TISSUE PROTEINS; RNA INTERFERENCE; WEIGHT LOSS;

EID: 84897570494     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.289     Document Type: Article

References (50)

1. The Huntington Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983 (1993
2. Gourfinkel-An, I, Cancel, G, Duyckaerts, C, Faucheux, B, Hauw, JJ, Trottier, Y et al. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. Neuroreport 9: 1823-1826 (1998
3. Vonsattel, JP, Myers, RH, Stevens, TJ, Ferrante, RJ, Bird, ED and Richardson, EP Jr (1985). Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577
4. Heinsen, H, Strik, M, Bauer, M, Luther, K, Ulmar, G, Gangnus, D et al. (1994). Cortical and striatal neurone number in Huntington's disease. Acta Neuropathol 88: 320-333
5. Yanagisawa, N (1992). The spectrum of motor disorders in Huntington's disease. Clin Neurol Neurosurg 94 Suppl: S182-S184
6. Spargo, E, Everall, IP and Lantos, PL (1993). Neuronal loss in the hippocampus in Huntington's disease: A comparison with HIV infection. J Neurol Neurosurg Psychiatr 56: 487-491
7. Gabery, S, Murphy, K, Schultz, K, Loy, CT, McCusker, E, Kirik, D et al. (2010). Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathol 120: 777-788
8. Rodda, RA (1981). Cerebellar atrophy in Huntington's disease. J Neurol Sci 50: 147-157
9. Aziz, NA, van der Burg, JM, Landwehrmeyer, GB, Brundin, P, Stijnen, T and Roos, RA; EHDI Study Group (2008). Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71: 1506-1513
10. Trejo, A, Tarrats, RM, Alonso, ME, Boll, MC, Ochoa, A and Velásquez, L (2004). Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20: 192-196
11. Tabrizi, SJ, Langbehn, DR, Leavitt, BR, Roos, RA, Durr, A, Craufurd, D et al.; TRACK-HD investigators. (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol 8: 791-801
12. van der Burg, JM, Björkqvist, M and Brundin, P (2009). Beyond the brain: Widespread pathology in Huntington's disease. Lancet Neurol 8: 765-774
13. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825
14. Rodriguez-Lebron, E, Denovan-Wright, EM, Nash, K, Lewin, AS and Mandel, RJ (2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12: 618-633
15. Franich, NR, Fitzsimons, HL, Fong, DM, Klugmann, M, During, MJ and Young, D (2008). AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 16: 947-956
16. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallele-specific silencing of mutant and wild-Type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063
17. Drouet, V, Perrin, V, Hassig, R, Dufour, N, Auregan, G, Alves, S et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65: 276-285
18. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044
19. McBride, JL, Pitzer, MR, Boudreau, RL, Dufour, B, Hobbs, T, Ojeda, SR et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19: 2152-2162
20. Ramaswamy, S and Kordower, JH (2012). Gene therapy for Huntington's disease. Neurobiol Dis 48: 243-254
21. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65
22. Saleh, N, Moutereau, S, Durr, A, Krystkowiak, P, Azulay, JP, Tranchant, C et al. (2009). Neuroendocrine disturbances in Huntington's disease. PLoS ONE 4: E4962
23. Strong, TV, Tagle, DA, Valdes, JM, Elmer, LW, Boehm, K, Swaroop, M et al. (1993). Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 5: 259-265
24. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873
25. Boudreau, RL, Spengler, RM and Davidson, BL (2011). Rational design of therapeutic siRNAs: Minimizing off-Targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 19: 2169-2177
26. Gray, M, Shirasaki, DI, Cepeda, C, André, VM, Wilburn, B, Lu, XH et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195
27. Fu, H, Muenzer, J, Samulski, RJ, Breese, G, Sifford, J, Zeng, X et al. (2003). Selfcomplementary adeno-Associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 8: 911-917
28. Fu, H, Dirosario, J, Killedar, S, Zaraspe, K and McCarty, DM (2011). Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-bloodbrain barrier gene delivery. Mol Ther 19: 1025-1033
29. McCarty, DM, DiRosario, J, Gulaid, K, Muenzer, J and Fu, H (2009). Mannitolfacilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 16: 1340-1352
30. Tasset, I, Sánchez-López, F, Agüera, E, Fernández-Bolaños, R, Sánchez, FM, Cruz-Guerrero, A et al. (2012). NGF and nitrosative stress in patients with Huntington's disease. J Neurol Sci 315: 133-136
31. Hult, S, Soylu, R, Björklund, T, Belgardt, BF, Mauer, J, Brüning, JC et al. (2011). Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metab 13: 428-439
32. Schilling, G, Becher, MW, Sharp, AH, Jinnah, HA, Duan, K, Kotzuk, JA et al. (1999). Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-Terminal fragment of huntingtin. Hum Mol Genet 8: 397-407
33. McBride, JL, Ramaswamy, S, Gasmi, M, Bartus, RT, Herzog, CD, Brandon, EP et al. (2006). Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 103: 9345-9350
34. Yu, ZX, Li, SH, Evans, J, Pillarisetti, A, Li, H and Li, XJ (2003). Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 23: 2193-2202
35. Cheng, Y, Peng, Q, Hou, Z, Aggarwal, M, Zhang, J, Mori, S et al. (2011). Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. Neuroimage 56: 1027-1034
36. Andreassen, OA, Dedeoglu, A, Ferrante, RJ, Jenkins, BG, Ferrante, KL, Thomas, M et al. (2001). Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8: 479-491
37. Boutin, S, Monteilhet, V, Veron, P, Leborgne, C, Benveniste, O, Montus, MF et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-Associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712
38. Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR and Samulski, RJ (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol Ther 19: 1058-1069
39. Samaranch, L, Salegio, EA, San Sebastian, W, Kells, AP, Foust, KD, Bringas, JR et al. (2012). Adeno-Associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 23: 382-389
40. Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C et al. (2007). Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110: 1132-1140
41. Ciesielska, A, Hadaczek, P, Mittermeyer, G, Zhou, S, Wright, JF, Bankiewicz, KS et al. (2013). Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cellmediated immune responses. Mol Ther 21: 158-166
42. Xu L, Lu PJ, Wang CH, Keramaris E, Qiao C, Xiao B et al. Adeno-Associated virus 9 mediated FKRP gene therapy restores functional glycosylation of alpha-dystroglycan and improves muscle functions. Mol Ther 21: 1832-1840 (2013
43. Karakikes, I, Chaanine, AH, Kang, S, Mukete, BN, Jeong, D, Zhang, S et al. (2013). Therapeutic cardiac-Targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2: E000078
44. Katwal, AB, Konkalmatt, PR, Piras, BA, Hazarika, S, Li, SS, John Lye, R et al. (2013). Adeno-Associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery. Gene Ther 20: 930-938
45. Sabatino, DE, Lange, AM, Altynova, ES, Sarkar, R, Zhou, S, Merricks, EP et al. (2011). Efficacy and safety of long-Term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 19: 442-449
46. Benkhelifa-Ziyyat, S, Besse, A, Roda, M, Duque, S, Astord, S, Carcenac, R et al. (2013). Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 21: 282-290
47. Gadalla, KK, Bailey, ME, Spike, RC, Ross, PD, Woodard, KT, Kalburgi, SN et al. (2013). Improved survival and reduced phenotypic severity following AAV9/ MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther 21: 18-30
48. Garg, SK, Lioy, DT, Cheval, H, McGann, JC, Bissonnette, JM, Murtha, MJ et al. (2013). Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci 33: 13612-13620
49. Foust, KD, Salazar, DL, Likhite, S, Ferraiuolo, L, Ditsworth, D, Ilieva, H et al. (2013). Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol Ther 21: 2148-2159
50. Smith, RH, Levy, JR and Kotin, RM (2009). A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-Titer rAAV stocks from insect cells. Mol Ther 17: 1888-1896.